Patients with COVID-19 who have underlying chronic lung disease are at increased risk for developing severe illness. Pulmonologist Brian Southern, MD, recently authored a review article in Cleveland Clinic Journal of Medicine’s COVID-19 Curbside Consults series. In this article, he takes a closer look at what is known about ILD and sarcoidosis in the context of the pandemic and offers insights for managing care.
Mild symptoms and a quick recovery are common in most cases of sarcoidosis, but a minority of patients have significant morbidity and impaired quality of life because of multiorgan involvement. A new Cleveland Clinic study examines association between income and sarcoidosis outcomes, after controlling for socioeconomic and disease-related factors.
Kristin Highland, MD, discusses new potential pathways to treat scleroderma-associated interstitial lung disease.
Results from a just-published landmark trial could lead to the first-ever approved drug for the treatment of systemic scleroderma-associated interstitial lung disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An inside look into the ILD Clinic of a large, tertiary referral center.
Cleveland Clinic’s Rheumatic Lung Disease Program is currently engaged in three major multicenter trials whose common aim is to improve outcomes for patients with rheumatic disease and pulmonary hypertension or interstitial lung disease.
The SENSCIS® study, co-led by Cleveland Clinic’s Kristin Highland, MD, explores the use of nintedanib in patients with scleroderma-associated interstitial lung disease.
Approved vasodilation therapies generally don’t improve function in patients with pulmonary hypertension associated with connective tissue disease. The Catalyst study explores the use of bardoxolone in these patients.
The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
IPF is still underappreciated by pulmonologists and primary care physicians. This article attempts to close that information gap by offering an overview of available treatment modalities.